BR112015022617A2 - polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável - Google Patents
polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestávelInfo
- Publication number
- BR112015022617A2 BR112015022617A2 BR112015022617A BR112015022617A BR112015022617A2 BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2 BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2
- Authority
- BR
- Brazil
- Prior art keywords
- thermostable
- recombinant polypeptide
- expression vector
- immunogenic composition
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
resumo polipeptídeo, composição imunogênica, vetor de expressão recombinante e método de indução de reação imunológica polipeptídeos recombinantes oligoméricos termoestáveis, que apresentam pelo menos um epítopo antigênico da pré-fusão da proteína f do vírus sincicial respiratório (rsv), que compreende o ectodomínio de proteína f rsv, funcionalidade excluída na região hrb, domínios transmembrana e citoplasmático substituídos por um domínio de trimerização heteróloga e dois locais de divisão furina multibásicos funcionais, são úteis como componentes antigênicos em composições imunogênicas úteis em métodos de indução de reação imunológica e vacinação contra infecções por rsv.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/828,667 US9060975B2 (en) | 2013-03-14 | 2013-03-14 | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
PCT/EP2014/054804 WO2014140083A1 (en) | 2013-03-14 | 2014-03-12 | Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015022617A2 true BR112015022617A2 (pt) | 2017-10-31 |
Family
ID=50241453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015022617A BR112015022617A2 (pt) | 2013-03-14 | 2014-03-12 | polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável |
Country Status (8)
Country | Link |
---|---|
US (2) | US9060975B2 (pt) |
EP (2) | EP3178840A1 (pt) |
JP (1) | JP6285469B2 (pt) |
CN (2) | CN105246910A (pt) |
AU (1) | AU2014230822B2 (pt) |
BR (1) | BR112015022617A2 (pt) |
CA (1) | CA2905571A1 (pt) |
WO (1) | WO2014140083A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2778899T3 (es) | 2013-02-01 | 2020-08-12 | Medimmune Llc | Epítopos de proteína F del virus sincitial respiratorio |
EP2970981B1 (en) | 2013-03-14 | 2020-10-28 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
BR112018008708A2 (pt) * | 2015-10-29 | 2018-11-06 | Univ Emory | rsv quimérico, composições imunogênicas e métodos de uso |
PT3439672T (pt) * | 2016-04-05 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv |
PL3464331T3 (pl) * | 2016-05-30 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Stabilizowane przedfuzyjne białka F RSV |
CN113832116A (zh) * | 2017-01-12 | 2021-12-24 | 厦门大学 | 稳定呼吸道合胞病毒融合蛋白的方法 |
AU2018241252A1 (en) * | 2017-03-30 | 2019-10-03 | The University Of Queensland | Chimeric molecules and uses thereof |
MX2019011869A (es) | 2017-04-04 | 2020-01-09 | Univ Washington | Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. |
WO2019063844A1 (en) * | 2017-09-29 | 2019-04-04 | Universiteit Antwerpen | VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS |
CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
KR20200050264A (ko) * | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
CN109694400A (zh) * | 2019-01-31 | 2019-04-30 | 苏州高泓利康生物科技有限公司 | 一种表达呼吸道合胞病毒f蛋白及其制备方法 |
WO2020205986A1 (en) * | 2019-04-02 | 2020-10-08 | Sanofi | Antigenic multimeric respiratory syncytial virus polypeptides |
CN110054668B (zh) * | 2019-04-25 | 2021-09-10 | 北京交通大学 | 一种呼吸道合胞病毒融合前f蛋白及其应用 |
US20220306697A1 (en) | 2019-09-04 | 2022-09-29 | University Of Washington | Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use |
CN111303245B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种抗合胞病毒膜融合抑制剂 |
JP2023521183A (ja) * | 2020-04-22 | 2023-05-23 | ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション | 三量体を形成するインフルエンザウイルス表面タンパク質由来組換え赤血球凝集素タンパク質およびその用途 |
US20230174591A1 (en) * | 2020-05-19 | 2023-06-08 | National Research Council Of Canada | Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins |
CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0916726A1 (en) | 1997-11-13 | 1999-05-19 | Rijksuniversiteit te Groningen | Attaching substances to micro-organisms |
EP1395648B1 (en) | 2001-06-11 | 2009-04-22 | Applied NanoSystems B.V. | Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
DK2445526T3 (en) | 2009-06-24 | 2016-06-27 | Glaxosmithkline Biologicals Sa | Recombinant RSV antigens. |
EA201270062A1 (ru) * | 2009-06-24 | 2013-02-28 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК | Вакцина |
US20120164176A1 (en) * | 2009-07-15 | 2012-06-28 | Kurt Swanson | Rsv f protein compositions amd methods for making same |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
BR112013024157A2 (pt) | 2011-03-22 | 2016-12-06 | Mucosis Bv | composições imunogênicas em forma particulada e métodos para produção destas |
CA2835644C (en) | 2011-05-13 | 2021-06-15 | Novartis Ag | Pre-fusion rsv f antigens |
-
2013
- 2013-03-14 US US13/828,667 patent/US9060975B2/en not_active Ceased
-
2014
- 2014-03-12 BR BR112015022617A patent/BR112015022617A2/pt not_active IP Right Cessation
- 2014-03-12 CN CN201480022815.8A patent/CN105246910A/zh active Pending
- 2014-03-12 AU AU2014230822A patent/AU2014230822B2/en not_active Ceased
- 2014-03-12 CA CA2905571A patent/CA2905571A1/en not_active Abandoned
- 2014-03-12 WO PCT/EP2014/054804 patent/WO2014140083A1/en active Application Filing
- 2014-03-12 EP EP16200916.1A patent/EP3178840A1/en not_active Withdrawn
- 2014-03-12 EP EP14709318.1A patent/EP2970393B1/en not_active Not-in-force
- 2014-03-12 CN CN201710040168.9A patent/CN107029227A/zh active Pending
- 2014-03-12 JP JP2015562115A patent/JP6285469B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-26 US US15/081,854 patent/USRE47471E1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN105246910A (zh) | 2016-01-13 |
JP2016510983A (ja) | 2016-04-14 |
US9060975B2 (en) | 2015-06-23 |
EP3178840A1 (en) | 2017-06-14 |
JP6285469B2 (ja) | 2018-02-28 |
CA2905571A1 (en) | 2014-09-18 |
USRE47471E1 (en) | 2019-07-02 |
AU2014230822B2 (en) | 2018-04-12 |
EP2970393A1 (en) | 2016-01-20 |
AU2014230822A1 (en) | 2015-10-01 |
US20140271696A1 (en) | 2014-09-18 |
CN107029227A (zh) | 2017-08-11 |
EP2970393B1 (en) | 2017-01-11 |
WO2014140083A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015022617A2 (pt) | polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável | |
CL2021001750A1 (es) | Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020) | |
EA201891415A8 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
BR112018075032A2 (pt) | proteínas de hemaglutinina do vírus influenza e seus uso | |
TR201903074T4 (tr) | Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler. | |
MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
AU2019349036A8 (en) | Immune composition, preparation method therefor, and application thereof | |
BR112016019525A2 (pt) | construções de proteína uspa2 e seu uso | |
EA202191622A1 (ru) | Стабилизированные растворимые f-белки rsv до слияния | |
EA202092521A1 (ru) | Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
MX2018003298A (es) | Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo. | |
AR095482A1 (es) | Virus del síndrome reproductivo y respiratorio porcino, composiciones, vacuna y métodos de uso | |
MX2019007349A (es) | Vacuna combinada para cerdos. | |
MX2018016121A (es) | Preparacion de anticuerpos monoclonales marcados con 212pb. | |
WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
CL2017003341A1 (es) | Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso | |
BR112019001115A2 (pt) | proteínas de biofusão como vacinas anti-malária | |
MY179251A (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
MX2019007252A (es) | Metodos y composiciones para vacunas del virus del dengue. | |
MX2019006104A (es) | Conjugados inmunogenicos y uso de los mismos. | |
AU2018388102A1 (en) | Cross-immunizing antigen vaccine and method for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 2020-01-07 |